Expect a price pull-back in the near future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ETST declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
ETST broke above its upper Bollinger Band on January 07, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ETST entered a downward trend on January 06, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Momentum Indicator moved above the 0 level on January 06, 2025. You may want to consider a long position or call options on ETST as a result. In of 154 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for ETST just turned positive on December 24, 2024. Looking at past instances where ETST's MACD turned positive, the stock continued to rise in of 59 cases over the following month. The odds of a continued upward trend are .
ETST moved above its 50-day moving average on January 06, 2025 date and that indicates a change from a downward trend to an upward trend.
Following a +2 3-day Advance, the price is estimated to grow further. Considering data from situations where ETST advanced for three days, in of 155 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ETST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (15.873) is normal, around the industry mean (58.527). P/E Ratio (0.678) is within average values for comparable stocks, (90.460). ETST's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.947). Dividend Yield (0.000) settles around the average of (0.122) among similar stocks. P/S Ratio (87.719) is also within normal values, averaging (19.547).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Industry PharmaceuticalsOther
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
SAA | 27.24 | 0.32 | +1.18% |
ProShares Ultra SmallCap600 | |||
SECT | 56.15 | 0.61 | +1.10% |
Main Sector Rotation ETF | |||
MSFO | 18.17 | 0.17 | +0.94% |
YieldMax MSFT Option Income Strategy ETF | |||
DFSB | 50.80 | 0.03 | +0.06% |
Dimensional Global Sstby Fxd Inc ETF | |||
BMED | 25.71 | N/A | N/A |
iShares Health Innovation Active ETF |
A.I.dvisor tells us that ETST and RSCI have been poorly correlated (+22% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ETST and RSCI's prices will move in lockstep.
Ticker / NAME | Correlation To ETST | 1D Price Change % | ||
---|---|---|---|---|
ETST | 100% | -9.00% | ||
RSCI - ETST | 22% Poorly correlated | N/A | ||
CXXIF - ETST | 22% Poorly correlated | -1.02% | ||
ESALF - ETST | 14% Poorly correlated | +2.50% | ||
HLTRF - ETST | 12% Poorly correlated | N/A | ||
HKMPY - ETST | 10% Poorly correlated | N/A | ||
More |
Ticker / NAME | Correlation To ETST | 1D Price Change % |
---|---|---|
ETST | 100% | -9.00% |
Pharmaceuticals: Other industry (223 stocks) | 10% Poorly correlated | +0.11% |
Pharmaceuticals industry (309 stocks) | 9% Poorly correlated | +0.20% |